US government sets the tone for Global Fund talks with $4.3 billion pledge

1 September 2016

The US government has announced plans to contribute $4.3 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Subject to approval from Congress and ongoing support from the government succeeding the Obama administration, the USA will make this further contribution to a fund to which it is the leading supporter as the provider of around one third of overall funding.

The announcement, made on Wednesday in Washington DC, comes shortly before a Global Fund Replenishment Conference in Montreal later this month, which will be attended by world leaders and decision-makers, and will set funding for the next three years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK